Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Akiko Iwasaki and Gregg Gonsalves named among “50 experts to trust in a pandemic”
Yale Professor of Immunology Akiko Iwasaki and Assistant Professor of Epidemiology Gregg Gonsalves ’11 GRD ’17 were named on the “50 experts to trust in a pandemic” list. The list, curated by editors of the health and wellness publication “Elemental,” presents 50 professionals that people should follow on social media for evidence-based guidance during the pandemic.Source: Yale Daily News
Immune System Variation Can Predict Severe COVID-19 Outcomes
The differing immune system responses of patients with COVID-19 can help predict who will experience moderate and severe consequences of disease, according to a new study by Yale Cancer Center researchers published July 27 in the journal Nature.
Caroline Johnson Receives American Cancer Society Research Scholar Grant
Caroline Johnson, Ph.D., Assistant Professor of Epidemiology in the Department of Environmental Health Sciences at Yale School of Public Health and a member of Yale Cancer Center’s Cancer Microbiology Research Program, has received a four-year, $792,000 Research Scholar Grant from the American Cancer Society (ACS).
Once-Common Hysterectomy Technique Linked to Worse Uterine Cancer Outcomes
Every year, nearly 700,000 American women have surgery to remove their uterus (hysterectomy) or uterine fibroids (myomectomy). A laparoscopic surgical technique once commonly used in these procedures could be worsening the outcomes for women who have undiagnosed uterine cancer at the time of the procedure, Yale Cancer Center scientists report in the Journal of Clinical Oncology.
Yale Cancer Center Researchers Show Adding Radiation After Immunotherapy Improves Survival Time for Patients with Advanced Lung Cancer
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
Bristol-Myers Squibb's Opdivo Shows 5-Year Survival Benefit in Lung Cancer
Bristol-Myers Squibb released the pooled efficacy and safety results from its Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced non-small cell lung cancer (NSCLC).Source: BioSpace
Blavatnik Gift Will Fund Research into the Biology of Survival
Medzhitov and his research team are working to uncover the mechanisms underlying survival strategies—also known as maintenance programs—an endeavor that will both advance fundamental biology and provide new therapeutic targets to prevent and treat disease.Source: Medicine@Yale
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.